Lumos Pharma, Inc. (Lumos Pharma) and NewLink Genetics Corporation (NewLink Genetics) today announced that by an overwhelming majority, NewLink Genetics’ stockholders have voted to approve the issuance of shares in connection with the merger combining NewLink Genetics with Lumos Pharma. The completion of the merger is expected to be effective in the coming days. The combined company will assume the name, Lumos Pharma, Inc., and will trade on Nasdaq under the stock symbol “LUMO.” The combined company will focus on the development and commercialization of innovative therapeutics for rare and neglected diseases.
Read the full article: NewLink Genetics Stockholders Approve Merger with Lumos Pharma //
Source: https://www.globenewswire.com/news-release/2020/03/18/2002543/0/en/NewLink-Genetics-Stockholders-Approve-Merger-with-Lumos-Pharma.html